Reverse transcriptase inhibitors induce cell differentiation and enhance the immunogenic phenotype in human renal clear-cell carcinoma

International Journal of Cancer

Volumn 122, Issue 12, 2008, Pages 2842-2850

  Landriscina, Matteo ^a   Altamura, Settimia Anna ^a   Roca, Leonarda ^a   Gigante, Margherita ^a   Piscazzi, Annamaria ^a   Cavalcanti, Elisabetta ^b,c   Costantino, Eleonora ^a   Barone, Carlo ^d   Cignarelli, Mauro ^a   Gesualdo, Loreto ^a   Ranieri, Elena ^a,c  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c Strada Prov le Valenzano Casamassima   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

Author keywords

Differentiation; Immune response; Renal cell carcinoma; Reverse transcriptase; Vitamin D receptor

Indexed keywords

CALBINDIN; CD40 LIGAND; CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR7; CYTOCHROME P450; EFAVIRENZ; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VITAMIN D; VITAMIN D RECEPTOR;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CLEAR CELL CARCINOMA; DOWN REGULATION; EFFECTOR CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOGENICITY; KIDNEY CARCINOMA; LYMPHOCYTE CULTURE; MEMORY T LYMPHOCYTE; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL LINE, TUMOR; DNA PRIMERS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; KIDNEY NEOPLASMS; MICROSCOPY, CONFOCAL; PHENOTYPE; REVERSE TRANSCRIPTASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 43049089743     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23197     Document Type: Article

References (49)

1. D'Hondt V, Gil T, Lalami Y, Piccart M, Awada A. Will the dark sky over advanced cell carcinoma soon become brighter? Eur J Cancer 2005;41:1246-53.
2. Weiss RH, Lin PY. Kidney cancer: identification of novel targets for therapy. Kidney Int 2006;69:224-32.
3. Schendel DJ, Gansbacher B, Oberneder R, Kriegmair M, Hofstetter A, Riethmuller G, Segurado OG. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogenic tumor lines. J Immunol 1993;151:4209-20.
4. Caignard A, Guillard M, Gaudin C, Escudier B, Triebel F, Dietrich PY. In situ demonstration of renal-cell-carcinoma-specific T-cell clones. Int J Cancer 1996;66:564-70.
5. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000;163:408-17.
6. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ. Regression of metastatic renal cell carcinoma after nonmyeoloablative allogenic peripheral blood stem cell transplantation. N Engl J Med 2000;343:750-8.
7. Rini B, Zimmerman T, Stadler W, Gajewski TF, Vogelzang NJ. Allogenic stem cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol 2002;20:2017-24.
8. Landriscina M, Spadafora C, Cignarelli M, Barone C. Anti-tumor activity of non-nucleosidic reverse transcriptase inhibitors. Curr Pharmaceut Des 2007;13:737-47.
9. Ren J, Nichols C, Bird L, Chamberlain P, Weaver K, Short S, Stuart DI, Stammers DK. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. J Mol Biol 2001;312:795-05.
10. Menendez-Arias L. Targeting HIV: antiretroviral therapy and development of drug resistance. Trends Pharmacol Sci 2002;23:381-3.
11. Mangiacasale R, Pittoggi C, Sciamanna I, Careddu A, Mattei E, Lorenzini R, Travaglini L, Landriscina M, Barone C, Nervi C, Lavia P, Spadafora C. Exposure of normal and transformed cells to nevirapine, a reverse transcriptase inhibitors, reduces cell growth and promote differentiation. Oncogene 2003;22:2750-61.
12. Sciamanna I, Landriscina M, Pittoggi C, Quirino M, Mearelli C, Beraldi R, Mattei E, Serafino A, Cassano A, Sinibaldi-Vallebona P, Garaci E, Barone C, et al. Inhibition of endogenous reverse transcriptase antagonizes human tumor growth. Oncogene 2005;24:3923-31.
13. Spadafora C. Endogenous reverse transcriptase: a mediator of cell proliferation and differentiation. Cytogenet Genome Res 2004;105:346-50.
14. Deininger PL, Moran JV, Batzer MA, Kazazian HH. Mobile elements and mammalian genome evolution. Curr Opin Genet Dev 2003;13:651-8.
15. Poznanski AA, Calarco PG. The expression of intracisternal A particole genes in the preimplantation mouse embryo. Dev Biol 1991;143:271-81.
16. Mwenda JM. Biochemical characterization of a reverse transcriptase activity associated with retroviral-like particles isolated from human placental villous tissue. Cell Mol Biol 1993;39:317-28.
17. Branciforte D, Martin SL. Developmental and cell-type specificity of Line-1 expression in mouse testis implications for transposition. Mol Cell Biol 1994;14:2584-92.
18. Deragon JM, Sinnett D, Labuda D. Reverse transcriptase activity from human embryonal carcinoma cells NTera2D1. EMBO J 1990;9:3363-8.
19. Martin SL. Ribonucleoprotein particles with LINE-1 RNA in mouse embryonal carcinoma cells. Mol Cell Biol 1991;11:4804-7.
20. Landriscina M, Fabiano A, Altamura S, Bagalà C, Piscazzi A, Cassano A, Spadafora C, Giorgino F, Barone C, Cignarelli M. Reverse transcriptase inhibitors downregulate cell proliferation in vitro and in vivo and restore TSH signaling and iodine uptake in human thyroid anaplastic carcinoma. J Clin Endocrinol Metab 2005;90:5663-71.
21. Herr W, Ranieri R, Olson W, Zarour H, Gesualdo L, Storkus WJ. Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4+ and CD8+ T lymphocyte responses. Blood 2000;96:1857-64.
22. Meyer RG, Kreer T, Drexler I, Wolfel T, Herr W. The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8+ T lymphocytes in IFN-γ ELISPOT assays. J Immunol Methods 2002;259:95-110.
23. Berger U, Wilson P, McClelland RA, Colston K, Haussler MR, Pike JW, Coombes RC. Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues. J Clin Endocrinol Metab 1988;67:607-13.
24. 2+ handling. Kidney Int 2006;69:650-4.
25. Trydal T, Bakke A, Aksner L, Aarkog D. 1,25-Dihydroxyvitamin D3 receptor measurement in primary renal cell carcinoma and autologous normal kidney tissue. Cancer Res 1988;48:2458-61.
26. Venyaminov SY, Klimtchuk ES, Bajzer Z, Craig TA. Changes in structure and stability of calbindin-D (28K) upon calcium binding. Anal Biochem 2004;334:97-105.
27. Yasmin R, Williams RM, Xu M, Noy N. Nuclear import of the retinoid X receptor, the vitamin D receptor, and their mutual heterodimer. J Biol Chem 2005;280:40152-60.
28. Issa LL, Leong GM, Eisman JA. Molecular mechanism of vitamin D receptor action. Inflamm Res 1998;47:451-75.
29. Dwivedi PP, Omdahl JL, Kola I, Hume DA, May BK. Regulation of rat cytochrome P450C24 (CYP24) gene expression. Evidence for functional cooperation of Ras-activated Ets transcription factors with the vitamin D receptor in 1,25-dihydroxyvitamin D(3)-mediated induction. J Biol Chem 2000;275:47-55.
30. Ryschich E, Notzel T, Hinz U, Autschbach F, Ferguson J, Simon I, Weitz J, Frohlich B, Klar E, Buchler MW, Schmidt J. Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma. Clin Cancer Res 2005;11:498-504.
31. Tong AW, Stone MJ. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther 2003;10:1-13.
32. Staehler M, Rohrmann K, Haseke N, Stief CG, Siebeis M. Targeted agents for the treatment of advanced renal cell carcinoma. Curr Drug Targets 2005;6:835-46.
33. Hsu MY, Meier FE, Nesbit M, Hsu JY, Van Belle P, Elder DE, Herlyn M. E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down regulates expression of invasion-related adhesion receptors. Am J Pathol 2000;156:1515-25.
34. 131I uptake in a poorly-differentiated thyroid tumour in response to the reverse transcriptase inhibitor nevirapine. Lancet Oncol 2006;7:877-9.
35. Lowe L, Hansen CM, Senaratne S, Colston KW. Mechanisms implicated in the growth regulatory effects of vitamin D compounds in breast cancer cells. Recent Results Cancer Res 2003;164:99-110.
36. Moreno J, Krishnan AV, Feldman D. Molecular mechanisms mediating the anti-proliferative effects of Vitamin D in prostate cancer. J Steroid Biochem Mol Biol 2005;97(1/2):31-6.
37. 2+ handling. Kidney Int 2006;69:650-4.
38. Madej A, Puzianowska-Kuznicka M, Tanski Z, Nauman J, Nauman A. Vitamin D receptor binding to DNA is altered without the change in its expression in human renal clear cell cancer. Nephron Exp Nephrol 2003;93:150-7.
39. Banwell CM, MacCartney DP, Guy M, Miles AE, Uskokovic MR, Mansi J, Stewart PM, O'Neill LP, Turner BM, Colston KW, Campbell MJ. Altered nuclear receptor corepressor expression attenuates vitamin D receptor signaling in breast cancer cells. Clin Cancer Res 2006;12:2004-13.
40. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005;26:662-87.
41. Moulton VR, Bushar ND, Leeser AB, Patke AS, Farber DL. Divergent generation of heterogeneous memory CD4 T cells. J Immunol 2006;177:869-76.
42. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004;22:745-63.
43. Manjunath N, Shankar P, Wan J, Weninger W, Crowley MA, Hieshima K, Springer TA, Fan X, Shen H, Lieberman J, von Andrian UH. Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes. J Clin Invest 2001;108:871-8.
44. Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, Antia R, von Andrian UH, Ahmed R. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003;4:225-34.
45. Dorrschuck A, Schmidt A, Schnurer E, Gluckmann M, Albrecht C, Wolfel C, Lennerz V, Lifke A, Di Natale C, Ranieri E, Gesualdo L, Huber C, et al. CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expression. Blood 2004;104:2591-9.
46. Barkholt L, Bregni M, Remberger M, Blaise D, Peccatori J, Massenkeil G, Pedrazzoli P, Zambelli A, Bay JO, Francois S, Martino R, Bengala C, et al. Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann Oncol 2006;17:1134-40.
47. Berntsen A, Geertsen PF, Svane IM. Therapeutic dendritic cell vaccination of patients with renal cell carcinoma. Eur Urol 2006;50:34-43.
48. de Gramont A, Van Cutsem E. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology 2005;69:46-56.
49. Rini BI. VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices. Curr Oncol Rep 2006;8:85-9.